-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer is the leading cause of cancer deaths worldwide
.
Non-small cell lung cancer and small cell lung cancer are the two main types of lung cancer.
Lung cancer is the leading cause of cancer deaths worldwide
2021 Nian 11 Yue 8 days, Bristol-Myers Squibb (NYSE: BMY ) announced that, BMY III clinical study of CheckMate-816 study in the IB period to IIIA of resectable non-small cell lung cancer ( NSCLC patients) achieved in improving The primary research endpoint of event-free survival ( EFS )
Nivolumab is a PD-1 immune checkpoint inhibitor that uniquely uses the body's own immune system to help the body restore its anti- tumor immune response
Dr.
CheckMate-816 is a randomized, open-label, multi-center phase III clinical study, which aims to evaluate the efficacy of nivolumab combined with chemotherapy for neoadjuvant treatment of patients with resectable non-small cell lung cancer compared with chemotherapy alone.
"CheckMate-816 is the first neoadjuvant phase III clinical study of lung cancer immunity , confirming that neoadjuvant immune combination therapy can bring statistically significant and clinically significant benefits to patients with non-metastatic non-small cell lung cancer .
Previously, Navoli Uumab combined with chemotherapy has been proven to bring statistically significant improvement in the complete remission of tumor pathology without affecting the results of surgery.
The latest research results now show that it also prolongs the disease-free survival of patients and delays the disease.
Recurrence or death .
CheckMate-816 study were previously have been in the 2021 American Association for Cancer Research Annual Meeting ( pCR data) and 2021 announced the American Society of Clinical Oncology Annual Meeting (ending surgery)
2014 Nian 7 months, Wu Li You is satisfied that the world's first monoclonal antibody to obtain regulatory approval of PD-1 immune checkpoint inhibitor, is currently satisfied Wu Li You monoclonal antibody has more than 65 approved regions, including the United States, European Union, Japan and China
.
2015 Nian 10 months, Wu Li You monoclonal antibody and is satisfied that Iraq horses adalimumab injection for the first time to obtain regulatory approval for the treatment of metastatic melanoma, the combination therapy currently has more than 50 approved countries or regions, including the United States, The European Union and China
.
Leave a message here